Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention

Published:2019-04 Issue:7 Volume:12 Page:624-633
ISSN:1936-8798
Container-title:JACC: Cardiovascular Interventions
language:en
Short-container-title:JACC: Cardiovascular Interventions

Author:

Maeng Michael,Christiansen Evald Høj,Raungaard Bent,Kahlert Johnny,Terkelsen Christian Juhl,Kristensen Steen Dalby,Carstensen Steen,Aarøe Jens,Jensen Svend Eggert,Villadsen Anton Boel,Lassen Jens Flensted,Thim Troels,Eftekhari Ashkan,Veien Karsten Tange,Hansen Knud Nørregaard,Junker Anders,Bøtker Hans Erik,Jensen Lisette Okkels,Maeng Michael,Bøtker Hans Erik,Christiansen Evald Høj,Raungaard Bent,Jensen Svend Eggert,Hansen Henrik Steen,Jensen Lisette Okkels,Bargsteen Helle,Pedersen Helle,Jørgensen Lars P.,Ottosen Pia,Pedersen Karin M.,Thygesen Kristian,Sørensen Jacob Thorsted,Andersen Henning Rud,Kahlert Johnny

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Long-term safety and efficacy of platinum chromium everolimus-eluting stents in coronary artery disease: 5-year results from the PLATINUM trial;Kelly;J Am Coll Cardiol Intv,2017

2. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial;Maeng;Lancet,2014

3. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial;von Birgelen;Lancet,2016

4. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial;Kandzari;Lancet,2017

5. Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis);Kandzari;Circulation,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platinum chromium everolimus-eluting stents for the treatment of (complex) coronary artery disease; from SYNERGY™ to the MEGATRON™;Expert Review of Medical Devices;2024-05-13

2. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes;Catheterization and Cardiovascular Interventions;2023-12-13

3. Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents;Journal of Clinical Medicine;2023-10-24

4. Dual-therapy CD34 antibody-covered sirolimus-eluting COMBO stents versus sirolimus-eluting Orsiro stents in patients treated with percutaneous coronary intervention: the three-year outcomes of the SORT OUT X randomised clinical trial;EuroIntervention;2023-10

5. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT;International Journal of Cardiology;2023-07